Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Bayer signs €250m pact with India’s Curadev for STING drugs

Bayer signs €250m pact with India’s Curadev for STING drugs

started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Excessive signalling through cGAS–STING has been linked to a range of chronic and rare diseases, including neurodegenerative conditions like Parkinson’s,

Latest news

More from news
Approximately 3 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely. ... Based on what we felt was the state of the art in terms of understanding the pathogenesis of major diseases, especially neurodegenerative diseases, and

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    Nevertheless, strategies for developing successful therapeutic interventions are shifting. We have developed a five-point roadmap to successful treatments for Alzheimer’s disease and neurodegenerative diseases. ... Hyper-stimulation of microglial cells

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    The Dementia Consortium provides academic researchers with the funding, industry expertise and project management resources to capitalise on new drug targets for the treatment of the neurodegenerative diseases that cause dementia. ... Diseases include

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... Target early disease stages: It is probably true for all neurodegenerative diseases that symptoms

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Denali had also been busy having completed a $250m IPO in early December.  The company has a focus in neurodegenerative diseases and a technology,

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics